The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...

With a market cap of $21 billion, Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and ...

The company's revenue hinges on products like Spinraza, as well as new launches such as Wainua, which has achieved promising early market penetration, and Tryngolza (olezarsen). During Q4 ...

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...